BioCentury | Feb 18, 2016
Financial News

Corvidia raises $26M, licenses cardio candidate

Corvidia Therapeutics (Boston, Mass.) raised $26 million in a series A round and licensed cardiovascular mAb COR-001 from AstraZeneca plc (LSE:AZN; NYSE:AZN). Sofinnova Partners and Apple Tree Partners led the round. Corvidia said it would...
BioCentury | May 19, 2014
Company News

Ligand, AstraZeneca deal

Ligand partnered with AstraZeneca's Omthera Pharmaceuticals Inc. subsidiary to develop products to treat dyslipidemia, including hypertriglyceridemia. The products will use Ligand's LTP technology to improve the lipid-lowering activity of omega-3 fatty acids. Ligand is eligible...
BioCentury | May 12, 2014
Strategy

Build up to break up

Pfizer Inc. continues to give signals that the grand plan is to break itself up, and the reality looks like it absolutely needs AstraZeneca plc 's assets to make it work. Pfizer already has internally...
BioCentury | May 12, 2014
Clinical News

Epanova regulatory update

FDA approved an NDA from AstraZeneca for Epanova as an adjunct to diet and exercise to treat severe hypertriglyceridemia, defined as triglyceride levels >=500 mg/dL. AZ expects to launch Epanova in the U.S. in 4Q14,...
BioCentury | May 7, 2014
Company News

FDA approves AZ's Epanova for severe hypertriglyceridemia

FDA approved an NDA from AstraZeneca plc (LSE:AZN; NYSE:AZN) for Epanova as an adjunct to diet and exercise to treat severe hypertriglyceridemia, defined as triglyceride levels greater than or equal to 500 mg/dL. The pharma...
BioCentury | Mar 24, 2014
Company News

Novira management update

Novira Therapeutics Inc. , Radnor, Pa. Business: Infectious Hired: Christian Schade as CEO, formerly EVP and CFO of Omthera Pharmaceuticals Inc. , which AstraZeneca plc acquired WIR Staff...
BioCentury | Sep 23, 2013
Clinical News

Epanova regulatory update

AstraZeneca said FDA accepted for review an NDA for Epanova to treat severe hypertriglyceridemia, defined as triglyceride levels >=500 mg/dL. The PDUFA date is May 5, 2014. Epanova is an ultra-pure mixture of the free...
BioCentury | Sep 19, 2013
Company News

FDA accepts Epanova NDA

AstraZeneca plc (LSE:AZN; NYSE:AZN) said FDA accepted an NDA for Epanova to treat severe hypertriglyceridemia, defined as triglyceride levels greater than or equal to 500 mg/dL. The PDUFA date is May 5, 2014. Epanova is...
BioCentury | Aug 12, 2013
Finance

A disciplined crowd

Even though this year's class of newly public biotechs is showing a stellar performance in the aftermarket, some IPO candidates have been forced to limp out or shelve their plans altogether. This suggests investors continue...
BioCentury | Aug 12, 2013
Strategy

FibroGen's globetrotting

Seven years after its last major deal, FibroGen Inc. has now carved up worldwide rights to FG-4592 via its new deal with AstraZeneca plc . A key task for FibroGen is now to execute in China,...
Items per page:
1 - 10 of 54
BioCentury | Feb 18, 2016
Financial News

Corvidia raises $26M, licenses cardio candidate

Corvidia Therapeutics (Boston, Mass.) raised $26 million in a series A round and licensed cardiovascular mAb COR-001 from AstraZeneca plc (LSE:AZN; NYSE:AZN). Sofinnova Partners and Apple Tree Partners led the round. Corvidia said it would...
BioCentury | May 19, 2014
Company News

Ligand, AstraZeneca deal

Ligand partnered with AstraZeneca's Omthera Pharmaceuticals Inc. subsidiary to develop products to treat dyslipidemia, including hypertriglyceridemia. The products will use Ligand's LTP technology to improve the lipid-lowering activity of omega-3 fatty acids. Ligand is eligible...
BioCentury | May 12, 2014
Strategy

Build up to break up

Pfizer Inc. continues to give signals that the grand plan is to break itself up, and the reality looks like it absolutely needs AstraZeneca plc 's assets to make it work. Pfizer already has internally...
BioCentury | May 12, 2014
Clinical News

Epanova regulatory update

FDA approved an NDA from AstraZeneca for Epanova as an adjunct to diet and exercise to treat severe hypertriglyceridemia, defined as triglyceride levels >=500 mg/dL. AZ expects to launch Epanova in the U.S. in 4Q14,...
BioCentury | May 7, 2014
Company News

FDA approves AZ's Epanova for severe hypertriglyceridemia

FDA approved an NDA from AstraZeneca plc (LSE:AZN; NYSE:AZN) for Epanova as an adjunct to diet and exercise to treat severe hypertriglyceridemia, defined as triglyceride levels greater than or equal to 500 mg/dL. The pharma...
BioCentury | Mar 24, 2014
Company News

Novira management update

Novira Therapeutics Inc. , Radnor, Pa. Business: Infectious Hired: Christian Schade as CEO, formerly EVP and CFO of Omthera Pharmaceuticals Inc. , which AstraZeneca plc acquired WIR Staff...
BioCentury | Sep 23, 2013
Clinical News

Epanova regulatory update

AstraZeneca said FDA accepted for review an NDA for Epanova to treat severe hypertriglyceridemia, defined as triglyceride levels >=500 mg/dL. The PDUFA date is May 5, 2014. Epanova is an ultra-pure mixture of the free...
BioCentury | Sep 19, 2013
Company News

FDA accepts Epanova NDA

AstraZeneca plc (LSE:AZN; NYSE:AZN) said FDA accepted an NDA for Epanova to treat severe hypertriglyceridemia, defined as triglyceride levels greater than or equal to 500 mg/dL. The PDUFA date is May 5, 2014. Epanova is...
BioCentury | Aug 12, 2013
Finance

A disciplined crowd

Even though this year's class of newly public biotechs is showing a stellar performance in the aftermarket, some IPO candidates have been forced to limp out or shelve their plans altogether. This suggests investors continue...
BioCentury | Aug 12, 2013
Strategy

FibroGen's globetrotting

Seven years after its last major deal, FibroGen Inc. has now carved up worldwide rights to FG-4592 via its new deal with AstraZeneca plc . A key task for FibroGen is now to execute in China,...
Items per page:
1 - 10 of 54